Influenza Vaccine Market

Influenza Vaccine Market (Type: Inactivated and Live Attenuated; Valency: Quadrivalent and Trivalent; Age Group: Pediatric and Adult) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Influenza Vaccine Market Outlook 2031

  • The global industry was valued at US$ 4.0 Bn in 2022
  • It is projected to grow at a CAGR of 7.2% from 2022 to 2031 and reach more than US$ 7.2 Bn by 2031

Analysts’ Viewpoint

The global influenza vaccine market is expected to grow at a rapid pace in the next few years. This can be ascribed to surge in prevalence of flu, rise in awareness, increase in geriatric population, and government initiatives to promote vaccination. Surge in number of collaborations between market players and governments to ensure availability of flu vaccines, such as swine flu vaccine, in remote areas is expected accelerate market development.

Introduction of new vaccines and increase in adoption in developing and underdeveloped countries offer significant opportunities to market players. Key players are focusing on research and development of innovative influenza vaccines. However, volatility in prices of raw materials used in the manufacture of vaccines, high cost of flu vaccines, and limited awareness and access in developing countries are expected to hamper market progress.

Influenza Vaccine Market

Influenza Vaccine Market Introduction

Influenza vaccine, also known as flu shot, is a crucial tool in preventing and controlling the spread of the influenza virus. The flu virus is highly contagious and could cause severe symptoms such as fever, cough, body ache, and fatigue. Influenza vaccines are available in various forms, including the traditional injected vaccine and nasal spray vaccines. Injected vaccine contains inactivated or weakened strains of the flu virus, while nasal spray vaccine contains live but weakened strains of the virus. Both types of vaccine trigger the body's immune system to produce an immune response, which helps protect against future infections.

Influenza vaccines are recommended for everyone over the age of six months, especially for people who are at high risk of developing serious complications from the flu, such as the elderly, young children, pregnant women, and people with weakened immune systems. However, influenza vaccines may not provide complete protection against the flu, and the level of protection could vary depending on factors such as age, health status, and the match between the vaccine and the circulating flu strains. Despite these limitations, influenza vaccines are the most effective way to prevent and control the spread of the flu virus. Regular vaccination, combined with good hygiene practices, such as frequent hand washing and covering the mouth and nose while coughing or sneezing, could help prevent the spread of flu and reduce the risk of serious complications.

Advances in Healthcare Infrastructure and Introduction of New Vaccine Products

Development of robust healthcare infrastructure and introduction of new flu vaccine products are driving global influenza vaccine market growth. Increase in availability of vaccines and expansion of healthcare systems in developing countries are making it easier for people to access these lifesaving products. For instance, in 2021, several major pharmaceutical companies, such as Pfizer and Moderna, announced the launch of new, highly effective influenza vaccines that offer improved protection against a wider range of flu strains. These new vaccines are expected to bolster market development.

Surge in number of collaborations between market players and governments to ensure the availability of flu vaccines in remote areas is propelling the market. For instance, in 2019, GlaxoSmithKline announced collaboration with the Bill and Melinda Gates Foundation to increase access to flu vaccines in low- and middle-income countries.

Adoption of Inactivated Vaccines for People at Higher Risk of Complications from Flu

In terms of type, the inactivated segment dominated the global influenza vaccine market in 2022. Inactivated influenza vaccine is an important tool in preventing and controlling the spread of the flu virus. These vaccines, which are made from dead strains of the flu virus, are the most commonly used form of flu vaccines and are considered safe and effective. One of the key advantages of inactivated influenza vaccines is high level of safety. Since the virus strains used in these vaccines are dead, these cannot cause a live flu infection. This makes inactivated vaccines an ideal option for people who are at higher risk of serious complications from the flu, such as pregnant women, people with weakened immune systems, and young children.

Rise in demand for flu vaccines and increase in awareness about the severity of influenza are propelling the inactivated segment. In 2021, the World Health Organization (WHO) launched a global public awareness campaign to encourage people to get vaccinated against influenza due to the COVID-19 pandemic.

Quadrivalent Vaccines Protect Against Four Strains of Flu Virus

Based on valency, the quadrivalent segment dominated the global market in 2022. Quadrivalent influenza vaccines offer better protection against the flu virus. One of the key advantages of quadrivalent vaccines is increased effectiveness in preventing the flu. Unlike traditional trivalent vaccines, which protect against three strains of the flu virus, quadrivalent vaccines protect against four strains. These vaccines are able to keep pace with rapidly evolving flu viruses and provide better protection. This is particularly important given the unpredictable nature of the flu virus and rapid rate at which it can evolve and change.

High Number of Influenza Vaccines for Adults

In terms of age group, the adult segment accounted for largest global influenza vaccine market share in 2022. The adult population is much larger than the younger population. According to the World Population Review of 2020, the population of adults aged 18 and above was around 4.6 billion, while the population of children aged 12 to 18 was nearly 1.2 billion. Moreover, the number of influenza vaccines for pediatrics is less than that for adults. For instance, the Pfizer-BioNTech vaccine was the first COVID-19 vaccine approved in the U.S., and it was only approved for people aged 16 and above. Thus, the adult population is more likely to get vaccinated than the younger population.

Availability of Influenza Vaccines in Hospitals and Pharmacies

Based on distribution channel, the hospitals & pharmacies segment dominated the global influenza vaccine market in 2022. This is ascribed to increase in availability of flu shot vaccines, expansion of healthcare infrastructure, rise in demand for flu vaccines, and convenience & accessibility. Hospitals and pharmacies are typically located within reach of the majority of the population, and these offer the convenience of walk-in appointments or scheduled visits. This makes them an ideal place for people to receive flu vaccine, particularly given the growing emphasis on preventative healthcare. Pharmacists are well-positioned to provide advice and guidance about the flu vaccine, as well as to administer the vaccine. As flu vaccination becomes increasingly important for preventing the spread of flu, hospital and pharmacy distribution channels are poised to play a crucial role in ensuring that people have access to the vaccines they need to protect themselves and their communities.

Regional Analysis of Global Influenza Vaccine Market

North America is one of the largest markets for influenza vaccines. The market in the region is driven by high incidence of flu and well-established healthcare infrastructure. The Centers for Disease Control and Prevention (CDC) recommends that everyone aged six months and older should receive a flu vaccine each year. Furthermore, increase in awareness about the importance of flu vaccination is propelling the influenza vaccine market in North America.

Asia Pacific is an emerging market for influenza vaccines. The market in the region is driven by growing burden of flu and improving healthcare infrastructure. The number of flu cases has increased in countries, such as India, China, and Australia, in the past few years, leading to rise in influenza vaccine market demand. Rise in awareness about the importance of flu vaccination and increase in availability of vaccines are accelerating market growth in Asia Pacific.

Analysis of Key Players

The influenza vaccine market report includes vital information about leading influenza vaccine manufacturers operating in the global market. Key players are adopting strategies such as product launches, divestiture, mergers & acquisitions (M&A), and partnerships to strengthen their position in the market. Pfizer, Inc., Sanofi, GlaxoSmithKline (GSK), AstraZeneca, Merck & Co., Inc., Novartis AG, Roche Holding AG, Seqirus (CSL Limited), Johnson & Johnson and Daiichi Sankyo Company, Limited are the prominent players operating in the market.

Key Developments

  • In February 2021, Pfizer and BioNTech announced the approval of COVID-19 vaccine for emergency use in the U.S. This approval marked a major milestone in the global fight against COVID-19, and demonstrated the ability of pharmaceutical companies to quickly develop and bring to market vaccines for emerging infectious diseases.

Key players in the market has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Influenza Vaccine Market Snapshot

Attribute Detail
Size in 2022 US$ 4.0 Bn
Forecast (Value) in 2031 More than US$ 7.2 Bn
Compound Annual Growth Rate (CAGR) 7.2%
Forecast Period 2023-2031
Historical Data Available for 2017-2022
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.
Competition Landscape
  • Market share analysis/ranking by company (2022)
  • Company profiles section includes overview, product portfolio, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Type
    • Inactivated
    • Live Attenuated
  • Valency
    • Quadrivalent
    • Trivalent
  • Age Group
    • Pediatric
    • Adult
  • Distribution Channel
    • Hospitals & Pharmacies
    • Government & Institutional Supply
    • Others
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa
Companies Profiled
  • Pfizer, Inc.
  • Sanofi
  • GlaxoSmithKline (GSK)
  • AstraZeneca
  • Merck & Co., Inc.
  • Novartis AG
  • Roche Holding AG
  • Seqirus (CSL Limited)
  • Johnson & Johnson
  • Daiichi Sankyo Company, Limited.
  • Sanofi-GSK
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global Influenza vaccine market in 2022?

The global market was valued at US$ 4.0 Bn in 2022

How big will it be by 2031?

It is projected to reach more than US$ 7.2 Bn by 2031

What will be the CAGR during the forecast period?

The CAGR is anticipated to be 7.2% from 2023 to 2031

Which are the prominent trends that affect growth?

Rise in awareness about influenza, improving healthcare infrastructure, and introduction of new vaccine products

Which segment accounted for major share?

The quadrivalent segment held the largest share in 2022

Which region will account for significant share?

North America is expected to account for leading share during the forecast period

Who are the prominent players in the global market?

Pfizer, Inc., Sanofi, GlaxoSmithKline (GSK), AstraZeneca, Merck & Co., Inc., Novartis AG, Roche Holding AG, Seqirus (CSL Limited), Johnson & Johnson, and Daiichi Sankyo Company, Limited

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Influenza Vaccine Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Type Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Influenza Vaccine Market Analysis and Forecast, 2017-2031

    5. Key Insights

        5.1. Reimbursement Scenario by Region/globally

        5.2. Diseases Incidence and prevalence

        5.3. Regulatory scenario in key region/Countries

        5.4. Covid-19 Impact on Industry

    6. Global Influenza Vaccine Market Analysis and Forecast, by Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Type, 2017-2031

            6.3.1. Inactivated

            6.3.2. Live Attenuated

        6.4. Market Attractiveness Analysis, by Type

    7. Global Influenza Vaccine Market Analysis and Forecast, by Valency

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Valency, 2017-2031

            7.3.1. Quadrivalent

            7.3.2. Trivalent

        7.4. Market Attractiveness Analysis, by Valency

    8. Global Influenza Vaccine Market Analysis and Forecast, by Age Group

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Age Group, 2017-2031

            8.3.1. Pediatric

            8.3.2. Adult

        8.4. Market Attractiveness Analysis, by Age Group

    9. Global Influenza Vaccine Market Analysis and Forecast, by Distribution Channel

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value Forecast, by Distribution Channel, 2017-2031

            9.3.1. Hospitals & Pharmacies

            9.3.2. Government & Institutional Supply

            9.3.3. Others

        9.4. Market Attractiveness Analysis, by Distribution Channel

    10. Global Influenza Vaccine Market Analysis and Forecast, by Region

        10.1. Key Findings

        10.2. Market Value Forecast, by Region

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness Analysis, by Region

    11. North America Influenza Vaccine Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Type, 2017-2031

            11.2.1. Inactivated

            11.2.2. Live Attenuated

        11.3. Market Value Forecast, by Valency, 2017-2031

            11.3.1. Quadrivalent

            11.3.2. Trivalent

        11.4. Market Value Forecast, by Age Group, 2017-2031

            11.4.1. Pediatric

            11.4.2. Adult

        11.5. Market Value Forecast, by Distribution Channel, 2017-2031

            11.5.1. Hospitals & Pharmacies

            11.5.2. Government & Institutional Supply

            11.5.3. Others

        11.6. Market Value Forecast, by Country, 2017-2031

            11.6.1. U.S.

            11.6.2. Canada

        11.7. Market Attractiveness Analysis

            11.7.1. By Type

            11.7.2. By Valency

            11.7.3. By Age Group

            11.7.4. By Distribution Channel

            11.7.5. By Country

    12. Europe Influenza Vaccine Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Type, 2017-2031

            12.2.1. Inactivated

            12.2.2. Live Attenuated

        12.3. Market Value Forecast, by Valency, 2017-2031

            12.3.1. Quadrivalent

            12.3.2. Trivalent

        12.4. Market Value Forecast, by Age Group, 2017-2031

            12.4.1. Pediatric

            12.4.2. Adult

        12.5. Market Value Forecast, by Distribution Channel, 2017-2031

            12.5.1. Hospitals & Pharmacies

            12.5.2. Government & Institutional Supply

            12.5.3. Others

        12.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Spain

            12.6.5. Italy

            12.6.6. Rest of Europe

        12.7. Market Attractiveness Analysis

            12.7.1. By Type

            12.7.2. By Valency

            12.7.3. By Age Group

            12.7.4. By Distribution Channel

            12.7.5. By Country/Sub-region

    13. Asia Pacific Influenza Vaccine Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Type, 2017-2031

            13.2.1. Inactivated

            13.2.2. Live Attenuated

        13.3. Market Value Forecast, by Valency, 2017-2031

            13.3.1. Quadrivalent

            13.3.2. Trivalent

        13.4. Market Value Forecast, by Age Group, 2017-2031

            13.4.1. Pediatric

            13.4.2. Adult

        13.5. Market Value Forecast, by Distribution Channel, 2017-2031

            13.5.1. Hospitals & Pharmacies

            13.5.2. Government & Institutional Supply

            13.5.3. Others

        13.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            13.6.1. China

            13.6.2. Japan

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Market Attractiveness Analysis

            13.7.1. By Type

            13.7.2. By Valency

            13.7.3. By Age Group

            13.7.4. By Distribution Channel

            13.7.5. By Country/Sub-region

    14. Latin America Influenza Vaccine Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Type, 2017-2031

            14.2.1. Inactivated

            14.2.2. Live Attenuated

        14.3. Market Value Forecast, by Valency, 2017-2031

            14.3.1. Quadrivalent

            14.3.2. Trivalent

        14.4. Market Value Forecast, by Age Group, 2017-2031

            14.4.1. Pediatric

            14.4.2. Adult

        14.5. Market Value Forecast, by Distribution Channel, 2017-2031

            14.5.1. Hospitals & Pharmacies

            14.5.2. Government & Institutional Supply

            14.5.3. Others

        14.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Market Attractiveness Analysis

            14.7.1. By Type

            14.7.2. By Valency

            14.7.3. By Age Group

            14.7.4. By Distribution Channel

            14.7.5. By Country/Sub-region

    15. Middle East & Africa Influenza Vaccine Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Type, 2017-2031

            15.2.1. Inactivated

            15.2.2. Live Attenuated

        15.3. Market Value Forecast, by Valency, 2017-2031

            15.3.1. Quadrivalent

            15.3.2. Trivalent

        15.4. Market Value Forecast, by Age Group, 2017-2031

            15.4.1. Pediatric

            15.4.2. Adult

        15.5. Market Value Forecast, by Distribution Channel, 2017-2031

            15.5.1. Hospitals & Pharmacies

            15.5.2. Government & Institutional Supply

            15.5.3. Others

        15.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Market Attractiveness Analysis

            15.7.1. By Type

            15.7.2. By Valency

            15.7.3. By Age Group

            15.7.4. By Distribution Channel

            15.7.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Player - Competition Matrix (by tier and size of companies)

        16.2. Market Share Analysis, by Company (2022)

        16.3. Company Profiles

            16.3.1. Pfizer, Inc.

                16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.1.2. Type Portfolio

                16.3.1.3. Financial Overview

                16.3.1.4. SWOT Analysis

                16.3.1.5. Strategic Overview

            16.3.2. Sanofi

                16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.2.2. Type Portfolio

                16.3.2.3. Financial Overview

                16.3.2.4. SWOT Analysis

                16.3.2.5. Strategic Overview

            16.3.3. GlaxoSmithKline (GSK)

                16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.3.2. Type Portfolio

                16.3.3.3. Financial Overview

                16.3.3.4. SWOT Analysis

                16.3.3.5. Strategic Overview

            16.3.4. AstraZeneca

                16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.4.2. Type Portfolio

                16.3.4.3. Financial Overview

                16.3.4.4. SWOT Analysis

                16.3.4.5. Strategic Overview

            16.3.5. Merck & Co., Inc.

                16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.5.2. Type Portfolio

                16.3.5.3. Financial Overview

                16.3.5.4. SWOT Analysis

            16.3.6. Novartis AG

                16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.6.2. Type Portfolio

                16.3.6.3. Financial Overview

                16.3.6.4. SWOT Analysis

            16.3.7. Roche Holding AG

                16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.7.2. Type Portfolio

                16.3.7.3. Financial Overview

                16.3.7.4. SWOT Analysis

            16.3.8. Seqirus (CSL Limited)

                16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.8.2. Type Portfolio

                16.3.8.3. Financial Overview

                16.3.8.4. SWOT Analysis

            16.3.9. Johnson & Johnson

                16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.9.2. Type Portfolio

                16.3.9.3. Financial Overview

            16.3.10. Daiichi Sankyo Company, Limited

                16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.10.2. Type Portfolio

                16.3.10.3. Financial Overview

                16.3.10.4. SWOT Analysis

    List of Tables

    Table 01: Global Influenza Vaccine Market Value (US$ Mn) Forecast, by Type, 2017-2031

    Table 02: Global Influenza Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017-2031

    Table 03: Global Influenza Vaccine Market Value (US$ Mn) Forecast, by Valency, 2017-2031

    Table 04: Global Influenza Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 05: Global Influenza Vaccine Market Value (US$ Mn) Forecast, by Region, 2017-2031

    Table 06: North America Influenza Vaccine Market Value (US$ Mn) Forecast, by Country, 2017-2031

    Table 07: North America Influenza Vaccine Market Value (US$ Mn) Forecast, by Type, 2017-2031

    Table 08: North America Influenza Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017-2031

    Table 09: North America Influenza Vaccine Market Value (US$ Mn) Forecast, by Valency, 2017-2031

    Table 10: North America Influenza Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 11: Europe Influenza Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 12: Europe Influenza Vaccine Market Value (US$ Mn) Forecast, by Type, 2017-2031

    Table 13: Europe Influenza Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017-2031

    Table 14: Europe Influenza Vaccine Market Value (US$ Mn) Forecast, by Valency, 2017-2031

    Table 15: Europe Influenza Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 16: Asia Pacific Influenza Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 17: Asia Pacific Influenza Vaccine Market Value (US$ Mn) Forecast, by Type, 2017-2031

    Table 18: Asia Pacific Influenza Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017-2031

    Table 19: Asia Pacific Influenza Vaccine Market Value (US$ Mn) Forecast, by Valency, 2017-2031

    Table 20: Asia Pacific Influenza Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 21: Latin America Influenza Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 22: Latin America Influenza Vaccine Market Value (US$ Mn) Forecast, by Type, 2017-2031

    Table 23: Latin America Influenza Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017-2031

    Table 24: Latin America Influenza Vaccine Market Value (US$ Mn) Forecast, by Valency, 2017-2031

    Table 25: Latin America Influenza Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 26: Middle East & Africa Influenza Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 27: Middle East & Africa Influenza Vaccine Market Value (US$ Mn) Forecast, by Type, 2017-2031

    Table 28: Middle East & Africa Influenza Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017-2031

    Table 29: Middle East & Africa Influenza Vaccine Market Value (US$ Mn) Forecast, by Valency, 2017-2031

    Table 30: Middle East & Africa Influenza Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    List of Figures

    Figure 01: Global Influenza Vaccine Market Value (US$ Mn) Forecast, 2017-2031

    Figure 02: Global Influenza Vaccine Market Value Share, by Type (2022)

    Figure 03: Global Influenza Vaccine Market Value Share, by Valency (2022)

    Figure 04: Global Influenza Vaccine Market Value Share, by Age Group (2022)

    Figure 05: Global Influenza Vaccine Market Value Share, by Distribution Channel (2022)

    Figure 06: Global Influenza Vaccine Market Value Share, by Region (2022)

    Figure 07: Global Influenza Vaccine Market Value Share Analysis, by Type, 2022 and 2031

    Figure 08: Global Influenza Vaccine Market Attractiveness Analysis, by Type, 2023-2031

    Figure 09: Global Influenza Vaccine Market Value Share Analysis, by Age Group, 2022 and 2031

    Figure 10: Global Influenza Vaccine Market Attractiveness Analysis, by Age Group, 2023-2031

    Figure 11: Global Influenza Vaccine Market Value Share Analysis, by Valency, 2022 and 2031

    Figure 12: Global Influenza Vaccine Market Attractiveness Analysis, by Valency, 2023-2031

    Figure 13: Global Influenza Vaccine Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 14: Global Influenza Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 15: Global Influenza Vaccine Market Value Share Analysis, by Region, 2022 and 2031

    Figure 16: Global Influenza Vaccine Market Attractiveness Analysis, by Region, 2022-2031

    Figure 17: North America Influenza Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 18: North America Influenza Vaccine Market Value Share Analysis, by Country, 2022 and 2031

    Figure 19: North America Influenza Vaccine Market Attractiveness Analysis, by Country, 2023-2031

    Figure 20: North America Influenza Vaccine Market Value Share Analysis, by Type, 2022 and 2031

    Figure 21: North America Influenza Vaccine Market Attractiveness Analysis, by Type, 2023-2031

    Figure 22: North America Influenza Vaccine Market Value Share Analysis, by Age Group, 2022 and 2031

    Figure 23: North America Influenza Vaccine Market Attractiveness Analysis, by Age Group, 2023-2031

    Figure 24: North America Influenza Vaccine Market Value Share Analysis, by Valency, 2022 and 2031

    Figure 25: North America Influenza Vaccine Market Attractiveness Analysis, by Valency, 2023-2031

    Figure 26: North America Influenza Vaccine Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 27: North America Influenza Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 28: Europe Influenza Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 29: Europe Influenza Vaccine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 30: Europe Influenza Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 31: Europe Influenza Vaccine Market Value Share Analysis, by Type, 2022 and 2031

    Figure 32: Europe Influenza Vaccine Market Attractiveness Analysis, by Type, 2023-2031

    Figure 33: Europe Influenza Vaccine Market Value Share Analysis, by Age Group, 2022 and 2031

    Figure 34: Europe Influenza Vaccine Market Attractiveness Analysis, by Age Group, 2023-2031

    Figure 35: Europe Influenza Vaccine Market Value Share Analysis, by Valency, 2022 and 2031

    Figure 36: Europe Influenza Vaccine Market Attractiveness Analysis, by Valency, 2023-2031

    Figure 37: Europe Influenza Vaccine Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 38: Europe Influenza Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 39: Asia Pacific Influenza Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 40: Asia Pacific Influenza Vaccine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 41: Asia Pacific Influenza Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 42: Asia Pacific Influenza Vaccine Market Value Share Analysis, by Type, 2022 and 2031

    Figure 43: Asia Pacific Influenza Vaccine Market Attractiveness Analysis, by Type, 2023-2031

    Figure 44: Asia Pacific Influenza Vaccine Market Value Share Analysis, by Age Group, 2022 and 2031

    Figure 45: Asia Pacific Influenza Vaccine Market Attractiveness Analysis, by Age Group, 2023-2031

    Figure 46: Asia Pacific Influenza Vaccine Market Value Share Analysis, by Valency, 2022 and 2031

    Figure 47: Asia Pacific Influenza Vaccine Market Attractiveness Analysis, by Valency, 2023-2031

    Figure 48: Asia Pacific Influenza Vaccine Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 49: Asia Pacific Influenza Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 50: Latin America Influenza Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 51: Latin America Influenza Vaccine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 52: Latin America Influenza Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 53: Latin America Influenza Vaccine Market Value Share Analysis, by Type, 2022 and 2031

    Figure 54: Latin America Influenza Vaccine Market Attractiveness Analysis, by Type, 2023-2031

    Figure 55: Latin America Influenza Vaccine Market Value Share Analysis, by Age Group, 2022 and 2031

    Figure 56: Latin America Influenza Vaccine Market Attractiveness Analysis, by Age Group, 2023-2031

    Figure 57: Latin America Influenza Vaccine Market Value Share Analysis, by Valency, 2022 and 2031

    Figure 58: Latin America Influenza Vaccine Market Attractiveness Analysis, by Valency, 2023-2031

    Figure 59: Latin America Influenza Vaccine Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 60: Latin America Influenza Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 61: Middle East & Africa Influenza Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 62: Middle East & Africa Influenza Vaccine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 63: Middle East & Africa Influenza Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 64: Middle East & Africa Influenza Vaccine Market Value Share Analysis, by Type, 2022 and 2031

    Figure 65: Middle East & Africa Influenza Vaccine Market Attractiveness Analysis, by Type, 2023-2031

    Figure 66: Middle East & Africa Influenza Vaccine Market Value Share Analysis, by Age Group, 2022 and 2031

    Figure 67: Middle East & Africa Influenza Vaccine Market Attractiveness Analysis, by Age Group, 2023-2031

    Figure 68: Middle East & Africa Influenza Vaccine Market Value Share Analysis, by Valency, 2022 and 2031

    Figure 69: Middle East & Africa Influenza Vaccine Market Attractiveness Analysis, by Valency, 2023-2031

    Figure 70: Middle East & Africa Influenza Vaccine Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 71: Middle East & Africa Influenza Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 72: Global Influenza Vaccine Market Share Analysis, by Company, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved